Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Abilify Has 4% New Rx Share; Sales Force Size To Increase 50%

Executive Summary

Bristol-Myers Squibb/Otsuka's Abilify has captured a 4% share of new antipsychotic prescriptions since its November launch, Bristol CEO Peter Dolan told investors on a first quarter conference call April 29

You may also be interested in...



Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk

Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)

Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk

Pfizer is highlighting the incidence of diabetes associated with "some atypical antipsychotics" in its promotions for Geodon (ziprasidone)

Bristol Abilify To Launch In Late November; Antipsychotic Approved Nov. 15

Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) will be launched by the end of November following FDA's Nov. 15 approval of the atypical antipsychotic

Related Content

UsernamePublicRestriction

Register

PS041723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel